Market Overview

UPDATE: Citigroup Reiterates Buy Rating, Raises PT on Dr. Reddy's Laboratories After Disappointing 3Q

Share:
Related RDY
Credit Suisse Prescribes Underperform Rating For Dr. Reddy's With Drop In U.S. Sales
Benzinga's Weekend M&A Chatter

In a report published Friday, Citigroup reiterated its Buy rating on Dr. Reddy's Laboratories (NYSE: RDY), and raised its price target to $39.36.

Citigroup noted, “We rate DRL Buy with a Target Price of $39.36. REDY, in our view, is among the best placed to capitalize on the multiple growth drivers for pharma over the next 3-4 years. We expect the U.S. (limited competition oppys, rising share in old products), India (sales force addition, new launches) and Russia (OTC push, fast growing market) to drive growth in the medium term, while biosimilars and the emerging markets deal with GSK contribute longer-term. With several catalysts lined up & attractive valuations, we think it is a good time to buy the stock.”

Dr. Reddy's Laboratories closed on Thursday at $34.82.

Latest Ratings for RDY

DateFirmActionFromTo
Jul 2016HSBCDowngradesHoldReduce
Jul 2016JefferiesDowngradesHoldUnderperform
Jul 2016Credit SuisseDowngradesNeutralUnderweight

View More Analyst Ratings for RDY
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (RDY)

View Comments and Join the Discussion!